Methylprednisolone clinical trials
Methylprednisolone is named as an intervention in 75 current clinical trials in our China, USA, France, Italy, Spain, Canada, UK, Denmark, Australia, Brazil, Germany, Israel, Poland, Belgium, Mexico, Turkey, Sweden, Czechia, Netherlands, Japan, Switzerland, Austria, Portugal, Norway, Taiwan, Ireland, South Korea, Singapore and Egypt registers. 41 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Hoffmann-La Roche (6). The most-studied condition is Chronic Graft-versus-host-disease. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.
Where Methylprednisolone is approved
All regulators →Of the three regulators tracked here, the first to approve Methylprednisolone was the US, on 24 Oct 1957.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Methylprednisolone
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Methylprednisolone works
All drug targets →- Glucocorticoid receptor agonist AgonistTarget: NR3C1 nuclear receptor subfamily 3 group C member 1✓ In ChEMBL and the Guide to Pharmacology
- Bell's palsyPhase 3
- COVID-19–associated multisystem inflammatory syndrome in childrenPhase 3
- Acoustic neuromaPhase 3
- Acute myeloid leukemiaPhase 3
- Acute respiratory distress syndromePhase 3
- Ischemic strokePhase 3
- Sudden sensorineural hearing lossPhase 3
- COVID-19Phase 2
- HeadachePhase 2
- Acute graft versus host diseasePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201081, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7088, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Methylprednisolone
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Methylprednisolone
- ChEMBL
- CHEMBL1201081
- PubChem CID
- 23680530
- CAS number
- 2375-03-3
- FDA UNII
- LEC9GKY20K
- Wikidata
- Q27282942
- Wikipedia
- Methylprednisolone succinate
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Methylprednisolone
75 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Methylprednisolone in the EU trials register (CTIS)
4 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Methylprednisolone. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Methylprednisolone across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
7 single-substance products containing Methylprednisolone on the HPRA medicines list.
- Depo-Medrone 40 mg/ml Suspension for Injection 1 ml vialPfizer Healthcare Ireland Unlimited Company · PA0822/122/001 · Marketed
- Depo-Medrone 40 mg/ml Suspension for Injection 2 ml vialPfizer Healthcare Ireland Unlimited Company · PA0822/122/002 · Marketed
- Depo-Medrone 40 mg/ml Suspension for Injection 3 ml vialPfizer Healthcare Ireland Unlimited Company · PA0822/122/003 · Marketed
- Solu-Medrone powder and solvent for solution for injection or concentrate for solution for infusion 1000 mg/vialPfizer Healthcare Ireland Unlimited Company · PA0822/136/004 · Marketed
- Solu-Medrone powder and solvent for solution for injection or concentrate for solution for infusion 125 mg/vialPfizer Healthcare Ireland Unlimited Company · PA0822/136/002 · Marketed
Supply shortages
- Methylprednisolone Acetate InjectionUS (FDA) · Current · updated 6 Nov 2026
Recent approvals
- Methylprednisolone AcetateFDA · 2 Nov 2026 · Generic (ANDA) · Gland
Conditions studied with Methylprednisolone
102 conditionsAll 102 conditions
| Condition (as registered) | Trials |
|---|---|
| Chronic Graft-versus-host-disease | 2 |
| Multiple Sclerosis | 2 |
| Systemic Lupus Erythematosus | 2 |
| Lupus Nephritis | 2 |
| Multiple Myeloma | 2 |
| Graves Ophthalmopathy | 2 |
| Neuromyelitis Optica Spectrum Disorders | 2 |
| B Acute Lymphoblastic Leukemia | 2 |
| Plasma Cell Myeloma | 1 |
| Frontotemporal Dementia | 1 |
| Plasma Cell Myeloma Recurrent | 1 |
| Gaucher Disease, Type 2 | 1 |
| Kidney Transplant Rejection | 1 |
| Optic Neuritis | 1 |
| Multiple Myeloma in Relapse | 1 |
| Multiple Myeloma, Refractory | 1 |
| Primary Membranous Nephropathy | 1 |
| Parkinson Disease | 1 |
| Plasma Cell Myeloma Refractory | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| X-Linked Myotubular Myopathy | 1 |
| Transcatheter Aortic Valve Replacemen | 1 |
| Left Bundle Branch Block | 1 |
| Drug Induced Liver Injury | 1 |
| Brain Metastases From Solid Tumors | 1 |
| Chronic Lymphocytic Leukemia | 1 |
| Small Lymphocytic Lymphoma | 1 |
| Neuromyelitis Optica Spectrum Disorder Attack | 1 |
| Thyroid Eye Disease | 1 |
| Thymoma | 1 |
| Relapsed/Refractory Multiple Myeloma | 1 |
| Lupus or SLE | 1 |
| Interstitial Lung Disease | 1 |
| Biliary Atresia | 1 |
| Cholangitis | 1 |
| Anti-Bacterial Agents | 1 |
| Acute Ischemic Stroke | 1 |
| Thyroid Eye Disease, TED | 1 |
| Optic Neuropathy | 1 |
| Unruptured Intracranial Aneurysms | 1 |
| Cerebrovascular Event | 1 |
| Hemorrhagic Stroke | 1 |
| Methylprednisolone | 1 |
| Outcome | 1 |
| Sudden Hearing Loss | 1 |
| Obstructive Sleep Apnea | 1 |
| GVHD, Acute | 1 |
| Stem Cell Transplant Complications | 1 |
| Extranodal NK T Cell Lymphoma | 1 |
| Hemophagocytic Lymphohistiocytosis (HLH) | 1 |
| Acute Gastrointestinal Graft-versus-host Disease | 1 |
| IgA Nephropathy (IgAN) | 1 |
| Antibody-mediated Rejection | 1 |
| Antibody-Mediated Rejection (AMR) | 1 |
| Ischemic Stroke, Acute | 1 |
| Immune Checkpoint Inhibitor-Related Pneumonitis | 1 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Neoplasms | 1 |
| Henoch-Schönlein Purpura | 1 |
| Sepsis | 1 |
| Acute Respiratory Distress Syndrome | 1 |
| Traumatic Brain Injury | 1 |
| Osteoporosis | 1 |
| Inflammatory Rheumatism | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| Mixed Phenotype Acute Leukemia | 1 |
| T Acute Lymphoblastic Leukemia | 1 |
| Paediatric Stroke | 1 |
| Elective Surgery for Any Digestive Cancer | 1 |
| Paraneoplastic Sensory Neuronopathy | 1 |
| Acute Myocarditis | 1 |
| Myocarditis Acute | 1 |
| Calcium Pyrophosphate Deposition Disease | 1 |
| Chondrocalcinosis | 1 |
| Cluster Headache | 1 |
| Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial | 1 |
| Community Acquired Pneumonia (CAP) | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 |
| Colitis | 1 |
| STEMI - ST Elevation Myocardial Infarction | 1 |
| Relapsing Remitting Multiple Sclerosis | 1 |
| Secondary Progressive Multiple Sclerosis | 1 |
| Primary Progressive Multiple Sclerosis | 1 |
| Thyroid-Associated Ophthalmopathy | 1 |
| Sudden Sensorineural Hearing Loss | 1 |
| Neuromuscular Block, Residual | 1 |
| Pain | 1 |
| Postoperative Nausea | 1 |
| Adhesive Capsulitis of the Shoulder | 1 |
| Rejection; Transplant, Kidney | 1 |
| Rejection; Transplant, Pancreas | 1 |
| Sacro-iliac Joint Pain | 1 |
| Ann Arbor Stage IIB Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IIIB Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IVA Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IVB Hodgkin Lymphoma | 1 |
| B Lymphoblastic Lymphoma | 1 |
| Sacroiliac Joint Dysfunction | 1 |
| Sacro-Iliac Spondylosis | 1 |
| Lymphoma | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Idiopathic Pulmonary Fibrosis | 1 |
Sponsors
lead sponsor per trial+ 42 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Methylprednisolone trials
How many clinical trials are testing Methylprednisolone?
75 current trials in our China, USA, France, Italy, Spain, Canada, UK, Denmark, Australia, Brazil, Germany, Israel, Poland, Belgium, Mexico, Turkey, Sweden, Czechia, Netherlands, Japan, Switzerland, Austria, Portugal, Norway, Taiwan, Ireland, South Korea, Singapore and Egypt registers name Methylprednisolone (also registered as Medlone 21) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Methylprednisolone trials recruiting patients?
Yes. 41 of the 75 trials are recruiting: 15 with sites in China, 9 with sites in USA, 6 with sites in France, 6 with sites in Italy, 6 with sites in Spain, 7 with sites in Canada, 3 with sites in UK, 8 with sites in Denmark, 5 with sites in Australia, 3 with sites in Brazil, 3 with sites in Germany, 3 with sites in Israel, 2 with sites in Poland, 4 with sites in Belgium, 3 with sites in Mexico, 2 with sites in Turkey, 4 with sites in Sweden, 2 with sites in Czechia, 4 with sites in Netherlands, 2 with sites in Japan, 2 with sites in Switzerland, 3 with sites in Austria, 1 with sites in Portugal, 1 with sites in Norway, 1 with sites in Taiwan, 1 with sites in Ireland, 1 with sites in South Korea, 1 with sites in Singapore and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Methylprednisolone clinical trials?
Hoffmann-La Roche (6), Sanofi (5), Prevail Therapeutics (3) and Oncotherapeutics (3), among 57 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Methylprednisolone clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Methylprednisolone licensed in Ireland?
Yes. The HPRA medicines list includes 7 single-substance products containing Methylprednisolone, for example Depo-Medrone 40 mg/ml Suspension for Injection 1 ml vial (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Methylprednisolone shortage?
The registers we track list 1 entry for Methylprednisolone: US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Methylprednisolone works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Methylprednisolone works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Methylprednisolone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.